An interventional study of Multi-Detector Computed Tomography in Type2 Diabetes and Coronary Heart Disease, sponsored by JuFeng, Hsiao. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-05-06.
Sponsored by JuFeng, Hsiao · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Coronary Disease with a site in Taiwan — 2 open to participants now, 3 under way, none of them phase 3. Coronary Disease · Taiwan.
Among the 20 studies in Coronary Disease with a site in Taiwan, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 7 with no phase, and was the 15th registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →2 of the 20 studies in Coronary Disease with a site in Taiwan are open now. Recruiting first, the newest first:
Chang Gung University of Science and Technology · Sites in Taiwan
Ages 20+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 801 across the 15 interventional studies, 100 across the 5 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with JuFeng, Hsiao as lead sponsor.
JuFeng, Hsiao has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Coronary Disease with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate benefits of primary prevention of major coronary heart disease for asymptomatic coronary artery disease in type 2 diabetes mellitus based on the coronary artery calcium score Our proposal
Background The patients with type two diabetes mellites increased gradually and heart disease and cerebral vascular disease is the fourth leading cause of mortality. According to the National Health Insurance Research Database (NHIRD) till 2014, incidence of coronary heart disease is 25.2% and heart failure is 3.77%。Multiple complication including chronic kidney disease and cerebrovascular diseases were also well-known.
A systematic review study of scientific evidence from across the world in 2007-2017 revealed cardiovascular disease (CVD) affected 32.2% overall; 29.1% had atherosclerosis, 21.2% had coronary heart disease (CAD), 14.9% heart failure, 14.6% angina, 10.0% myocardial infarction and 7.6% stroke. CVD representing 50.3% of all deaths is a major cause of mortality among people with type 2 Diabetes mellitus (T2DM) (1).A study in Asian population revealed patients with diabetes had a 1.89-fold risk of all-cause death and 2.0-fold risk of cardiovascular death compared with patients without diabetes(2) . However, most diabetes with CAD are asymptomatic.
Coronary artery calcium (CAC) score measured by multi-detector computerized tomography is a reliable measure of subclinical atherosclerosis. The presence, extent and progression of CAC have been shown to predict adverse cardiovascular events better than traditional risk factors and global risk scoring (3-7)。Our previous study in 2020 revealed CAC score could predict long-term cardiovascular outcomes in asymptomatic patients with T2DM (8). 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease and 2019 ESC/EAS Guidelines for the management of dyslipidaemias recommend CAC score as a decision making aid for personalized risk management in primary prevention (9,10).This prospective cohort study will invest the impact of a coronary artery calcium-guided primary prevention of major coronary heart disease for asymptomatic coronary artery disease in T2DM.
Objective To evaluate benefits of primary prevention of major coronary heart disease for asymptomatic coronary artery disease in T2DM based on the coronary artery calcium score Our proposal
Method
Population:
The investigator will enroll 1500 asymptomatic T2DM patients who will receive Coronary artery calcium (CAC) imaging using 256 sliced multi-detector computerized tomography (MDCT) scanner as research group and 500 patients as control group from Lan-Yan Diabetes Shared Care Network (public health bureau, clinics, and regional hospital in Yilan County).
Inclusion criteria: more than 40 years old T2DM patients have any one cardiovascular risk as follows
CAC Scores Measurement Coronary artery calcium (CAC) imaging was performed using an 256 sliced multi-detector computerized tomography (MDCT) scanner (Philips Brilliance 256) equipped with high-resolution detectors.
Intervention for study group Based on 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease and 2019 ESC/EAS Guidelines for the management of dyslipidemias and result of CAC score(9-12), the investigator will recommend the in-charged doctor to control the cardiovascular risk factors more aggressively. The study protocols are as follows If CAC score >0, Treadmill ECG or Thallium201 Scan would be arranged. If Treadmill ECG or Thallium201 show significant ischemia, further study such as CT angiography or coronary angiography will be arranged.
If CAC score > 100, Aspirin 100mg QD will be suggested to decrease the cardiovascular risk in patients with low risk of bleeding. Previous studies revealed aspirin for patients with CAC score>100 at low bleeding risk indicated net benefit ( If CAC score > 400,statin therapy will be suggested to control lipidemia aggressively and target LDL level\<70 mg/dL The investigator will follow up these patients every 6 month, record their results of blood tests and medication for 5 years. Primary endpoint is major coronary heart disease including cardiac mortality, acute myocardial infarction, coronary revascularization. Second endpoint include all caused death, death due to cardiovascular disease, heart failure, stroke, admission for heart failure, chronic kidney disease and cost related to AMI, coronary heart disease, heart failure, stroke, chronic kidney disease etc.
Control group 500 age, gender, risk factor matched T2DM patients from our hospital will be enrolled. The doctor in charge will give usual care according to the Diabetes associate of Taiwan clinical practice guidelines for diabetes care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
more than 40 years old T2DM patients have any one cardiovascular risk as follows
Exclusion Criteria:
history of cardiovascular diseases such as coronary heart disease, stroke, heart failure etc, pregnant
1500 asymptomatic T2DM patients who will receive Coronary artery calcium (CAC) imaging using 256 sliced multi-detector computerized tomography (MDCT) scanner If CAC score \>0, Treadmill ECG or Thallium201 Scan would be arranged. If Treadmill ECG or Thallium201 show significant ischemia, further study such as CT angiography or coronary angiography will be arranged. If CAC score \> 100, Aspirin 100mg QD will be suggested to decrease the cardiovascular risk in patients with low risk of bleeding. Previous studies revealed aspirin for patients with CAC score\>100 at low bleeding risk indicated net benefit If CAC score \> 400,statin therapy will be suggested to control lipidemia aggressively and target LDL level\<70 mg/dL
Diagnostic Test: Multi-Detector Computed Tomography
The investigators will enroll 500 age, gender, risk factor matched T2DM patient from our hospital. The doctor in charge will give usual care according to the Diabetes associate of Taiwan clinical practice guidelines for diabetes care.
Coronary angiography calcium score via Multi-Detector Computed Tomography
rate of major coronary heart disease
cardiac mortality, acute myocardial infarction and coronary revascularization
Time frame: 5-year followup
rate of mortality
all caused death, death due to cardiovascular disease, heart failure and stroke
Time frame: 5-year followup
rate of admission
admission for heart failure, chronic kidney disease and stroke
Time frame: 5-year followup
medical expenditure
Medical expenditure, including both inpatient and outpatient costs, the total medical cost of index hospitalization due to Medical expenditure based on Taiwan National Health Insurance Research Database within 5 year- followup, including both outpatient costs and the total medical cost of hospitalization related to AMI, coronary heart disease, heart failure, stroke, chronic kidney disease
Time frame: 5-year followup
PDFs hosted by the registry, ClinicalTrials.gov.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2028, 81 months after the start.
Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 81 months is above that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.